Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of any of the following malignant gliomas:
• * Glioblastoma multiforme
• * Anaplastic astrocytoma
• * Grade 3 or greater WHO astrocytic, oligodendroglial, or mixed glial tumors that were initially diagnosed by histologic examination of a tumor specimen obtained from biopsy or resection
• Recurrent disease
• * No more than 3 prior recurrences
• Measurable recurrent or residual primary CNS neoplasm on contrast-enhanced MRI or CT scan
• No evidence of CNS hemorrhage on baseline MRI or CT scan
• PATIENT CHARACTERISTICS:
• Karnofsky performance status 60-100%
• Hematocrit \> 29%
• Absolute neutrophil count \> 1,500/mm³
• Platelet count \> 125,000/mm³
• Creatinine \< 1.5 mg/dL
• SGOT \< 1.5 times upper limit of normal (ULN)
• Bilirubin \< 1.5 times ULN
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No active infection
• No significant traumatic injury within the past 28 days
• PRIOR CONCURRENT THERAPY:
• At least 6 weeks since prior surgical resection
• More than 28 days since prior major surgical procedure or open biopsy
• More than 7 days since prior minor surgical procedure, fine-needle aspirations, or core biopsies
• At least 6 weeks since prior chemotherapy\*
• At least 4 weeks since prior radiotherapy\*
• No concurrent immunosuppressive agents
• No concurrent therapeutic anticoagulation
• Concurrent corticosteroids allowed if dose has been stable for 1 week prior to study entry NOTE: \* Unless there is unequivocal evidence of progressive disease